Literature DB >> 18053613

Induction of immune tolerance to facilitate beta cell regeneration in type 1 diabetes.

Lorenzo Pasquali1, Nick Giannoukakis, Massimo Trucco.   

Abstract

A definitive cure for type 1 diabetes is currently being pursued with enormous effort by the scientific community. Different strategies are followed to restore physiologic production of insulin in diabetic patients. Restoration of self-tolerance remains the milestone that must be reached in order to move a step further and recover a cell source capable of independent and functional insulin production. Multiple strategies aimed at modulation of both central and peripheral immunity must be considered. Promising results now show that the immune system can be modulated in a way that acquisition of a "diabetes-suppressive" phenotype is possible. Once self-tolerance is achieved, reversal of the disease may be obtained by simply allowing physiologic rescue and/or regeneration of the beta cells to take place. Given that these outcomes have already been confirmed in humans, refinement of existing protocols along with novel methods adapted to T1DM reversal will allow translation into clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 18053613     DOI: 10.1016/j.addr.2007.08.032

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  7 in total

Review 1.  Use of nonobese diabetic mice to understand human type 1 diabetes.

Authors:  Terri C Thayer; S Brian Wilson; Clayton E Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2010-07-08       Impact factor: 4.741

2.  Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease.

Authors:  H Ma; Y Lu; H Li; M Campbell-Thompson; M Parker; C Wasserfall; M Haller; M Brantly; D Schatz; M Atkinson; S Song
Journal:  Diabetologia       Date:  2010-07-01       Impact factor: 10.122

3.  A cell-based approach for diabetes treatment using engineered non-beta cells.

Authors:  Heather Bara; Peter M Thulé; Athanassios Sambanis
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

4.  Myeloid-derived suppressor cells prevent type 1 diabetes in murine models.

Authors:  Bingjiao Yin; Ge Ma; Chun-Yu Yen; Zuping Zhou; George X Wang; Celia M Divino; Sofia Casares; Shu-Hsia Chen; Wen-Chin Yang; Ping-Ying Pan
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

5.  Imaging the Beta-cell mass: why and how.

Authors:  Frantisek Saudek; Carl-Henrik Brogren; Srirang Manohar
Journal:  Rev Diabet Stud       Date:  2008-05-10

6.  Immunomodulatory strategies prevent the development of autoimmune emphysema.

Authors:  Masayuki Hanaoka; Mark R Nicolls; Andrew P Fontenot; Donatas Kraskauskas; Douglas G Mack; Adelheid Kratzer; Jonas Salys; Vita Kraskauskiene; Nana Burns; Norbert F Voelkel; Laimute Taraseviciene-Stewart
Journal:  Respir Res       Date:  2010-12-16

7.  CD33+ HLA-DR- Myeloid-Derived Suppressor Cells Are Increased in Frequency in the Peripheral Blood of Type1 Diabetes Patients with Predominance of CD14+ Subset.

Authors:  Mirhane Hassan; Hala M Raslan; Hesham Gamal Eldin; Eman Mahmoud; Hanaa Alm-Elhuda Abd Elwajed
Journal:  Open Access Maced J Med Sci       Date:  2018-02-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.